Hugel Expands Its Aesthetic Portfolio with ECM-Based Injectable Treatments

Hugel Inc. Expands into ECM-Based Injectable Market

Hugel Inc., a prominent player in the realm of medical aesthetics, is embarking on an expansion of its product line by entering the extracellular matrix (ECM)-based injectable market. The South Korean company, which has proven its strength in aesthetic medicine with products like botulinum toxin and dermal fillers, aims to enhance its offerings further through this initiative.

Strategic Collaboration for Domestic Distribution

On April 1, Hugel signed an agreement with Hans Biomed, a leading Korean medical materials manufacturer, to distribute CellREDM™, an ECM-based injectable treatment. This collaboration comes at a time when the demand for innovative aesthetic solutions in South Korea is surging. Hans Biomed is notable for being the first tissue bank operator in Asia to receive approval from the American Association of Tissue Banks (AATB), ensuring quality and ethical compliance in its products.

What is CellREDM™?

CellREDM™ is derived from human acellular dermal matrix (hADM) and is designed to promote skin regeneration. This injectable treatment works by supplementing the skin with necessary ECM components such as collagen and elastin, fostering natural regeneration and improving overall skin health. With its inclusion in Hugel's portfolio, the company aims to provide a more comprehensive set of solutions beyond traditional wrinkle reduction and volumization treatments.

Enhancing Medical Aesthetic Solutions

The addition of CellREDM™ is a significant leap for Hugel as it seeks to integrate cutting-edge products into its lineup. Historically, Hugel has concentrated on in-house innovations, but this strategic partnership represents its shift toward collaboration with third-party products. The company envisions creating synergistic effects between CellREDM™ and existing products, particularly dermal fillers, which are often used in concert during aesthetic procedures.

Co-Promotion Model to Boost Efficiency

Both Hugel and Hans Biomed have set out to employ a co-promotion model tailored to specialized clinics, which will enhance supply efficiency and accelerate market penetration. Geun Young Kim, CEO of Hans Biomed, emphasized that their partnership will highlight the superior quality of CellREDM™, minimizing post-procedure downtime and pain for patients. Similarly, Daniel Chang, Hugel's Korea CEO, expressed confidence that this agreement marks the beginning of an expansive phase for the company, reinforcing its commitment to innovation in the aesthetic market.

Future Developments in Aesthetic Materials

Hugel is not stopping with ECM-based injectables. The company is actively exploring additional innovative materials to diversify its offerings. Potential avenues include poly-L-lactic acid (PLLA), polycaprolactone (PCL), polynucleotide (PN), and polydeoxyribonucleotide (PDRN), indicative of its strategic vision toward broader aesthetic solutions.

A Legacy of Excellence

Founded in 2001, Hugel has emerged as a global leader in the medical aesthetics sector, providing a diverse array of injectables for skin rejuvenation and other cosmetic solutions. With a firm commitment to safety and quality, Hugel’s initiatives are further bolstered through robust medical affairs, training programs, and participation in industry forums. Its footprint spans approximately 70 countries, supported by nine global subsidiaries in regions including the US, Australia, and several parts of Asia.

As Hugel expands its horizons, it is evidently poised for sustained growth and influential market presence, continually adapting to the dynamic landscape of medical aesthetics. This recent foray into ECM-based injectables underscores its dedication to meeting evolving consumer needs and setting new industry standards.